Same Story with Different Endings in HER2- Positive Breast Cancer: Why the Benefit of Pertuzumab is Robust in the Metastatic Scenario and Modest in the Adjuvant Setting?_Crimson Publishers

Same Story with Different Endings in HER2- Positive Breast Cancer: Why the Benefit of Pertuzumab is Robust in the Metastatic Scenario and Modest in the Adjuvant Setting? by Shantata J Kudchadkar and Jayesh Sagar* in Crimson Publishers: Open access journal of surgery impact factor

While the incorporation of pertuzumab to a chemotherapy and trastuzumab backbone (dual HER2 blockade) yielded a robust improvement in the outcomes of HER2-positive metastatic patients in the CLEOPATRA study, in the adjuvant setting the same magnitude of benefit was not reproduced with the addition of pertuzumab in the overall population of the APHINITY study, being the reasons for this discrepancy unknown so far. In the present manuscript, we discuss biological and clinical differences between metastatic and early-stage HER2-positive breast cancer that may potentially explain the different magnitudes of benefit observed with pertuzumab in the different disease settings.

https://crimsonpublishers.com/smoaj/fulltext/SMOAJ.000560.php

For more articles on crimson publishers

Please click on link:  https://crimsonpublishers.com/

For more articles on Surgical Medicine Open Access Journal
Please click on link: https://crimsonpublishers.com/smoaj/index.php

Blogger
Follow On Publons  : https://publons.com/publisher/6342/crimson-publishers
Follow On Linkedin : https://www.linkedin.com/company/crimsonpublishers